Navigation Links
Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Date:7/30/2009

as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabi
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , 23 de julio de 2014 /PRNewswire/ ... o la Compañía) ha anunciado hoy una asociación ... (ABIA o el Instituto), para el ... un dispositivo de terapia de señal bioeléctrica (el ... El Instituto, que tiene una importante experiencia ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
(Date:7/23/2014)... Columbia, MD (PRWEB) July 23, 2014 ... Booth and ChirpE Mobile App, AACC Pathfinder, in its ... event offerings. AACC’s annual meeting is planned for July ... is the place to be to connect with global ... medicine, lab management, and other areas of breaking science ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... , T.J. Higley and Roy Eksteen, ... , Introduction: ... many variables are examined to ensure method , ... are required to be consistent by ...
... , , ... Tosoh has introduced two new columns , with differing surface ... selectivities for a wide range of sample types. , , ... In recent years, many new octadecylsilane (ODS) chemistries have been , ...
... Authors: T.J. Higley, Tosoh Bioscience LLC, Tatsunari Yoshida, Tosoh , ... , The TSKgel Amide-80 column provides excellent selectivity ... polar carbamoyl , functionalities bonded to a silica base material. ... Introduction: , The separation of peptides with many ...
Cached Biology Technology:Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column 2Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column 3TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80 2Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80 3Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80 4
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... around the world by 2050, according to one of ... Change (IPCC), may be advantageous to the physiology and ... of forage plants such as Stylosanthes capitata Vogel ... countries such as Brazil., The conclusion is from a ... Biology at the Ribeiro Preto Faculty of Philosophy, Sciences ...
(Date:7/23/2014)... of 2015, Springer will publish the International Journal ... journal of the Taiwan Fuzzy Systems Association (TFSA). The ... visibility in the area of fuzzy research., The ... presenting high-quality papers that deal with the theory, design ... systems and extension theory systems ranging from hardware to ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4
... your baby isn,t destined to a life of obesity after ... The FASEB Journal . In the report, ... during pregnancy to a moderate level is enough to benefit ... that a protein called "SIRT1" rewrites a developing fetus, histone ...
... of emission reduction measures are considerable. In order ... to develop uniform assessment methods for ensuring that ... practice., Significant mitigation of climate change is widely ... considerable reductions in global greenhouse gas emissions in ...
... product secreted by a soil bacterium shows promise as ... a new study published in EMBO Molecular Medicine ... shown how pyridomycin, a natural antibiotic produced by the ... candidate is active against many of the drug-resistant types ...
Cached Biology News:Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2Effectiveness and impact of climate change mitigation measures unclear 2Effectiveness and impact of climate change mitigation measures unclear 3Scientists reveal how natural antibiotic kills tuberculosis bacterium 2
... Mutagenesis System enables you to insert a ... target DNA by in vitro transposition. It ... randomly into the DNA target. Target DNA ... purified,chromosomal DNA, depending on your interests (6-8). ...
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
... N-terminal kinase (JNK) is one of the ... has been used as a sensitive reporter ... provides a 1000-fold increase in sensitivity in ... assay. Firefly luciferase catalyzes the oxidative carboxylation ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
Biology Products: